BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis

BACKGROUND: Anti-EGFR antibody–based treatment is an important therapeutic strategy for advanced colorectal cancer (CRC); despite this, several mutations—including KRAS, BRAF, and PIK3CA mutations, and HER2 amplification—are associated with the mechanisms underlying the development of resistance to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Nam, Soo Kyung, Yun, Sumi, Koh, Jiwon, Kwak, Yoonjin, Seo, An Na, Park, Kyoung Un, Kim, Duck-Woo, Kang, Sung-Bum, Kim, Woo Ho, Lee, Hye Seung
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4798471/
https://ncbi.nlm.nih.gov/pubmed/26991109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0151865
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky